Meet The Professor Management of Chronic Lymphocytic Leukemia

Philip A Thompson, MB, BS

Assistant Professor, Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas



Commercial Support

These activities are supported by educational grants from AbbVie Inc and AstraZeneca Pharmaceuticals LP.



Dr Love — Disclosures

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc. and Verastem Inc.



Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.




Dr Thompson — Disclosures

Advisory Committee and Contracted Research	AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, VelosBio
Other	CME Talks sponsored by Janssen Biotech Inc




We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.



Familiarizing Yourself with the Zoom Interface How to answer poll questions



When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.



ONCOLOGY TODAY WITH DR NEIL LOVE

Front-Line Treatment of Chronic Lymphocytic Leukemia




DR STEVEN COUTRE STANFORD UNIVERSITY SCHOOL OF MEDICINE









Dr Steven Coutre Front-Line Treatment Oncology Today with Dr Neil Love —

Meet The Professor Immunotherapy and Novel Agents in Gynecologic Cancers

> Monday, April 5, 2021 5:00 PM – 6:00 PM ET

Faculty Bradley J Monk, MD



Ask the Expert: Clinical Investigators Provide Perspectives on the Management of Renal Cell Carcinoma

> Tuesday, April 6, 2021 12:00 PM – 1:00 PM ET

Faculty Sumanta K Pal, MD



Meet The Professor Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal Cancers

> Thursday, April 8, 2021 5:00 PM – 6:00 PM ET

Faculty Dirk Arnold, MD, PhD



Ask the Investigators: Applying Emerging Clinical Research to the Care of Patients with Gastroesophageal Cancers

> Monday, April 12, 2021 6:30 PM – 7:30 PM ET

Faculty Joseph Chao, MD Yelena Y Janjigian, MD



Meet The Professor Management of Chronic Lymphocytic Leukemia

Thursday, April 15, 2021 5:00 PM – 6:00 PM ET

> Faculty John N Allan, MD



Dissecting the Decision: Investigator Perspectives on Key Issues in the Management of Common Cancers Breast Cancer

> Tuesday, April 20, 2021 8:30 AM – 10:00 AM ET

Faculty Carey K Anders, MD

Kathy D Miller, MD Sara M Tolaney, MD, MPH



Thank you for joining us!

CME and MOC credit information will be emailed to each participant within 5 business days.



Meet The Professor Management of Chronic Lymphocytic Leukemia

Philip A Thompson, MB, BS

Assistant Professor, Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas



Meet The Professor Program Participating Faculty



John N Allan, MD Assistant Professor of Medicine Weill Cornell Medicine New York, New York



Ian W Flinn, MD, PhD Director of Lymphoma Research Program Sarah Cannon Research Institute Tennessee Oncology Nashville, Tennessee



Steven Coutre, MD Professor of Medicine (Hematology) Stanford University School of Medicine Stanford, California



Prof John G Gribben, MD, DSc, FMedSci Chair of Medical Oncology Barts Cancer Institute Queen Mary University of London Charterhouse Square London, United Kingdom



Matthew S Davids, MD, MMSc Associate Professor of Medicine Harvard Medical School Director of Clinical Research Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts



Brian T Hill, MD, PhD Director, Lymphoid Malignancy Program Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio



Meet The Professor Program Participating Faculty



Nitin Jain, MD Associate Professor of Medicine Department of Leukemia The University of Texas MD Anderson Cancer Center Houston, Texas



John M Pagel, MD, PhD Chief of Hematologic Malignancies Center for Blood Disorders and Stem Cell Transplantation Swedish Cancer Institute Seattle, Washington



Brad S Kahl, MD Professor of Medicine Washington University School of Medicine Director, Lymphoma Program Siteman Cancer Center St Louis, Missouri



Kerry Rogers, MD Assistant Professor in the Division of Hematology The Ohio State University Columbus, Ohio



Anthony R Mato, MD, MSCE Associate Attending Director, Chronic Lymphocytic Leukemia Program Memorial Sloan Kettering Cancer Center New York, New York



Jeff Sharman, MD Willamette Valley Cancer Institute and Research Center Medical Director of Hematology Research US Oncology Eugene, Oregon



Meet The Professor Program Participating Faculty



Tanya Siddiqi, MD Associate Professor Director, Chronic Lymphocytic Leukemia Program Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte, California




William G Wierda, MD, PhD DB Lane Cancer Research Distinguished Professor Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas



Mitchell R Smith, MD, PhD Professor of Medicine Associate Center Director for Clinical Investigations Director, Division of Hematology and Oncology GW Cancer Center Washington, DC




Jennifer Woyach, MD Professor Division of Hematology Department of Internal Medicine The Ohio State University Comprehensive Cancer Center Columbus, Ohio



Philip A Thompson, MB, BSAssistant Professor, Department of LeukemiaDivision of Cancer MedicineThe University of Texas MD Anderson Cancer CenterHouston, Texas




We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.



Familiarizing Yourself with the Zoom Interface How to answer poll questions



When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.



ONCOLOGY TODAY WITH DR NEIL LOVE

Front-Line Treatment of Chronic Lymphocytic Leukemia




DR STEVEN COUTRE STANFORD UNIVERSITY SCHOOL OF MEDICINE









Dr Steven Coutre Front-Line Treatment Oncology Today with Dr Neil Love —

Meet The Professor Immunotherapy and Novel Agents in Gynecologic Cancers

> Monday, April 5, 2021 5:00 PM – 6:00 PM ET

Faculty Bradley J Monk, MD



Ask the Expert: Clinical Investigators Provide Perspectives on the Management of Renal Cell Carcinoma

> Tuesday, April 6, 2021 12:00 PM – 1:00 PM ET

Faculty Sumanta K Pal, MD



Meet The Professor Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal Cancers

> Thursday, April 8, 2021 5:00 PM – 6:00 PM ET

Faculty Dirk Arnold, MD, PhD



Ask the Investigators: Applying Emerging Clinical Research to the Care of Patients with Gastroesophageal Cancers

> Monday, April 12, 2021 6:30 PM – 7:30 PM ET

Faculty Joseph Chao, MD Yelena Y Janjigian, MD



Meet The Professor Management of Chronic Lymphocytic Leukemia

Thursday, April 15, 2021 5:00 PM – 6:00 PM ET

> Faculty John N Allan, MD



Dissecting the Decision: Investigator Perspectives on Key Issues in the Management of Common Cancers Breast Cancer

> Tuesday, April 20, 2021 8:30 AM – 10:00 AM ET

Faculty Carey K Anders, MD

Kathy D Miller, MD Sara M Tolaney, MD, MPH



Meet The Professor Management of Chronic Lymphocytic Leukemia

Philip A Thompson, MB, BS

Assistant Professor, Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas





John N Allan, MD Assistant Professor of Medicine Weill Cornell Medicine New York, New York



Current Role of Minimal Residual Disease Assessment in the Management of Multiple Myeloma and Chronic Lymphocytic Leukemia with Drs Shaji Kumar and Philip Thompson

Episode 57 · March 1, 2021

https://oncologytoday.researchtopractice.com/57



Episode Host Neil Love, MD



Dr Shaji Kumar Mayo Clinic



Dr Philip Thompson The University of Texas MD Anderson Cancer Center



Meet The Professor with Dr Thompson

MODULE 1: Cases from Dr Allan

- A 79-year-old man with significant cardiac history and symptomatic CLL (Parts 1, 2 and 3)
- A 93-year-old woman with symptomatic disease progression after response to obinutuzumab (Parts 1, 2 and 3)
- A 65-year-old man with significant cardiac history, AIHA (Parts 1 and 2)
- An 86-year-old man with relapsed CLL treated with ibrutinib/venetoclax

MODULE 2: Beyond the Guidelines

MODULE 3: Journal Club with Dr Thompson

MODULE 4: Key Recent Data Sets



A 79-year-old man with significant cardiac history and symptomatic CLL — Part 1



Dr John Allan

- PMH: CAD s/p STEMI 10/2018, multiple catheterizations, with > 5 DES stents placed, 2nd degree heart block; CVA in 2008
- 2016: Diagnosed with CLL
- 12/2018: Referred due to significant anemia (Hgb: 8), adenopathy
 - CLL work up: Unmutated IGHV, Del13q, NOTCH1, BCOR, MALT1, NF1, SAMHD1, TET2 mutations



A 79-year-old man with significant cardiac history and symptomatic CLL — Part 2



Dr John Allan

- PMH: CAD s/p STEMI 10/2018, multiple catheterizations, with > 5 DES stents placed, 2nd degree heart block; CVA in 2008
- 2016: Diagnosed with CLL
- 12/2018: Referred due to significant anemia (Hgb: 8), adenopathy
 - CLL work up: Unmutated IGHV, Del13q, NOTCH1, BCOR, MALT1, NF1, SAMHD1, TET2 mutations
- 2/2019: Obinutuzumab induction, with delayed venetoclax initiation until 5/2019 due to insurance
 8/2019: Essentially nCR, with one 2-cm residual node
- 7/2020: Peripheral blood MRD 0.03% → Treatment discontinued
- 10/2020: Diffuse adenopathy, worsening anemia, thrombocytopenia

Questions

• What do you think has happened? What would you do at this point to manage this patient?



A 79-year-old man with significant cardiac history and symptomatic CLL — Part 3

- PMH: CAD s/p STEMI 10/2018, multiple catheterizations, with > 5 DES stents placed, 2nd degree heart block; CVA in 2008
- 2016: Diagnosed with CLL
- 12/2018: Referred due to significant anemia (Hgb: 8), adenopathy
 - CLL work up: Unmutated IGHV, Del13q, NOTCH1, BCOR, MALT1, NF1, SAMHD1, TET2 mutations
- 2/2019: Obinutuzumab induction, with delayed venetoclax initiation until 5/2019 due to insurance
 8/2019: Essentially nCR, with one 2-cm residual node
- 7/2020: Peripheral blood MRD 0.03% → Treatment discontinued
- 10/2020: Diffuse adenopathy, worsening anemia (not transformed, no BCL mutation)
- Venetoclax re-ramp from 100 mg to 400 mg, with resolution of adenopathy

Questions

 Would you stop treatment if he continues venetoclax for another year or 2 years and achieves MRD negativity? If he is MRD-positive after that time, would you change treatment, or add another drug to venetoclax?



Dr John Allan



What is Minimal Residual Disease (MRD) in Hematologic Malignancies?

- Malignant cell populations present in low numbers, below the threshold for detection using standard morphologic techniques.
- "CR" in bone marrow in acute myeloid leukemia = <5% blasts: reduction from 10¹² to <5 x 10¹⁰ leukemic cells.¹
- "Minimal" may be a misnomer.

Why measure MRD in CLL?

- If MRD present, in the absence of further therapy, relapse will occur.
- Accurate quantitation of residual disease:
 - 1. Accurately determines prognosis.
 - 2. May guide treatment decisions.

When could we measure MRD?

- At completion of therapy (best established role):
 - 1. Determine prognosis.
 - 2. Guide use of consolidation therapy (potentially).
- During therapy to allow modification of treatment strategy (work in progress).
- During observation after completion of therapy to detect early relapse that may have a specific intervention (best established after alloSCT).

Why is MRD such a useful prognostic marker?

- Predictive of PFS and OS independent of clinical response and treatment received.
- Quantitative and functions as a continuous variable.

Conclusions from the 5-Year Analysis of MURANO

Most patients who completed Ven monotherapy had uMRD at EOT and MRD status continued to be a robust predictor of outcomes. Patients in the VenR arm with uMRD at EOT had a 61.3% PFS rate at 36 months post-EOT.



Median time to MRD conversion was 19 months and median time to PD from MRD conversion was a further 25 months for patients with uMRD at EOT. A significant proportion of patients remained with uMRD at this follow-up.

 \checkmark

Poor baseline characteristics are associated with faster MRD doubling rates.



Deep and durable initial response alongside favorable baseline characteristics predict sensitivity to re-treatment.



Sustained uMRD, PFS and OS benefits provide further support for the use of fixed duration VenR in patients with relapsed/refractory CLL.

Phase 2 CAPTIVATE Study Design (NCT02910583)



bCturtified by ICUN resultation

^bStratified by *IGHV* mutation status.

^cConfirmed undetectable MRD for randomization defined as undetectable MRD serially over at least 3 cycles in peripheral blood (PB), and undetectable MRD in both PB and BM.


Study Populations:

- MRD cohort (N=164): exposure and safety analysis
 - Safety Run-in: first 14 patients completed C15 treatment (12 cycles of I+V);
 no dose-limiting toxicities (DLT) or clinical TLS during first 6 weeks of I+V combination
 - Prespecified analysis of the first 30 patients who completed C9 treatment (6 cycles of I+V) for MRD evaluation
- Fixed Duration cohort (N=159): separate cohort; analysis not shown

Courtesy of Dr Philip A Thompson

ASCO 2018, 1142 Wierda et al.

CLARITY Study – relapsed CLL



A 93-year-old woman with symptomatic disease progression after response to obinutuzumab — Part 1

- 2010: Diagnosed with SLL, based on lymph node biopsy
- 2016: Elevated WBC to 81K, with increased adenopathy



Dr John Allan



A 93-year-old woman with symptomatic disease progression after response to obinutuzumab — Part 2

- 2010: Diagnosed with SLL, based on lymph node biopsy
- 2016: Elevated WBC to 81K, with increased adenopathy
- 2017: Diagnosed with CLL del13q, unmutated IGHV (NGS not performed due to insurance coverage)
- Obinutuzumab x 6 months, with normalization of blood counts, reduction in LAD, PR on imaging
- 8/2020: Increasing WBC to 43K, with increasing adenopathy

Questions

- How are you managing these older and frailer patients? What options would you consider for a
 patient like this obinutuzumab alone, chlorambucil? How do you view BTK inhibitors or venetoclaxbased therapies for a patient like this woman?
- When her WBC and adenopathy began increasing on obinutuzumab, what would you have done another round of treatment, or go to targeted agents? Which targeted agent would you use?





Dr John Allan

A 93-year-old woman with symptomatic disease progression after response to obinutuzumab — Part 3



Dr John Allan

- 2010: Diagnosed with SLL, based on lymph node biopsy
- 2016: Elevated WBC to 81K, with increased adenopathy
- 2017: Diagnosed with CLL del13q, unmutated IGHV (NGS not performed due to insurance coverage)
- Obinutuzumab x 6 months, with normalization of blood counts, reduction in LAD, PR on imaging
- 8/2020: Increasing WBC to 43K, with increasing adenopathy
- Acalabrutinib 100 mg BID
 - 9/2020: WBC 107K
 - 11/2020: WBC 63K, with decreasing adenopathy



A 65-year-old man with significant cardiac history, AIHA — Part 1

- Admitted for elective heart catherization, DES stent (dual antiplatelet agents)
 - WBC: 88K, ALC: 60K



Dr John Allan

- Diagnosed with CLL, deletion 11q+, IGHV unmutated (adenopathy < 5 cm, spleen 22 cm)
- Brisk autoimmune hemolytic anemia (AIHA) \rightarrow 6/2018: Obinutuzumab, with improvement

Questions

• Given the need for treatment and his brisk AIHA, what would be an appropriate approach for this patient at this time?



A 65-year-old man with significant cardiac history, AIHA — Part 2

- Admitted for elective heart catherization, DES stent (dual antiplatelet agents)
 - WBC: 88K, ALC: 60K
- Diagnosed with CLL, deletion 11q+, IGHV unmutated (adenopathy < 5 cm, spleen 22 cm)
- Brisk autoimmune hemolytic anemia (AIHA)
 - 6/2018: Obinutuzumab, with rapid improvement in WBC over the first 3 weeks, hemolysis essentially stopped by week 3
- Off protocol venetoclax initiated
- 6/2019 Bone marrow MRD: negative
- 10/2020 Peripheral blood MRD: negative

Questions

- Given his cardiac history, would you have considered a BTK inhibitor or would you have taken the approach that was taken?
- Are you following MRD in your clinical practice?
- Have you followed rapid dose escalation of venetoclax for high-risk patients, who are progressing rapidly? Do you have any risk mitigation strategies that have been helpful?



Dr John Allan



An 86-year-old man with relapsed CLL treated with ibrutinib/venetoclax

- August 2015: Diagnosed at age 81, ibrutinib initiated due to rising WBC count and anemia; counts returned to normal
 - Full CLL workup not performed prior to treatment by outside physician
 - Bone marrow biopsy: Complex karyotype with monosomy 17
- 2018: Patient referred due to outside physician moving out of state
- August 2020: WBC counts begin to rise to 20K with mild anemia and thrombocytopenia
- CLL evaluation:
 - Complex karyotype with monosomy 17, unmutated IGHV V3-23
 - ARID1A, CCND3, TP53 mutated, no BTK mutation

Question

- How often are you assessing for BTK mutations? How often are you repeat testing -- FISH testing, mutational testing -- on your patients when they are progressing on targeted agents?
- How would you manage this patient?







Meet The Professor with Dr Thompson

MODULE 1: Cases from Dr Allan

MODULE 2: Beyond the Guidelines

MODULE 3: Journal Club with Dr Thompson

- Occupy BTK: The key to controlling CLL
- Acalabrutinib for patients with relapsed/refractory CLL intolerant to ibrutinib
- Ibrutinib induces durable remissions in patients with treatment-naïve CLL with 17p deletion/TP53 mutations
- Achieving complete remission with ibrutinib: Clinical significance and predictive factors
- Prognostic value of measurable residual disease after venetoclax and decitabine for AML
- A multicenter Phase II study of venetoclax with dose-adjusted R-EPOCH (VR-EPOCH) for Richter's syndrome
- Clinical and molecular characteristics and treatment patterns of adolescents and young adults with CLL

MODULE 4: Key Recent Data Sets



What is your usual preferred initial regimen for a <u>60-year-old</u> patient with CLL with <u>IGHV mutation</u> but no del(17p) or TP53 mutation who requires treatment?

- 1. FCR (fludarabine/cyclosphosphamide/rituximab)
- 2. Ibrutinib
- 3. Ibrutinib + rituximab
- 4. Ibrutinib + obinutuzumab
- 5. Acalabrutinib
- 6. Acalabrutinib + obinutuzumab
- 7. Venetoclax + obinutuzumab
- 8. Other



What is your usual preferred initial regimen for a <u>60-year-old</u> patient with CLL with <u>IGHV mutation</u> but no del(17p) or TP53 mutation who requires treatment?

Dr Davids	Venetoclax + obinutuzumab	Dr Mato	FCR
Dr Flinn	Venetoclax + obinutuzumab	Dr Pagel	Acalabrutinib
Dr Hill	Venetoclax + obinutuzumab OR BR	Dr Rogers	Ibrutinib or FCR
Dr Jain	Venetoclax + obinutuzumab	Dr Siddiqi	Venetoclax + obinutuzumab

FCR = fludarabine/cyclosphosphamide/rituximab; BR = bendamustine/rituximab



What is your usual preferred initial regimen for a <u>75-year-old</u> patient with CLL with <u>IGHV mutation</u> but no del(17p) or TP53 mutation who requires treatment?

Dr Davids	Venetoclax + obinutuzumab	Dr Mato	Acalabrutinib
Dr Flinn	Acalabrutinib	Dr Pagel	Acalabrutinib
Dr Hill	Obinutuzumab	Dr Rogers	Acalabrutinib or venetoclax + obinutuzumab
Dr Jain	Venetoclax + obinutuzumab	Dr Siddiqi	Acalabrutinib + obinutuzumab



What is your usual preferred initial regimen for a <u>60-year-old</u> patient with CLL with <u>unmutated IGHV</u> and no del(17p) or TP53 mutation who requires treatment?

- 1. FCR
- 2. Ibrutinib
- 3. Ibrutinib + rituximab
- 4. Ibrutinib + obinutuzumab
- 5. Acalabrutinib
- 6. Acalabrutinib + obinutuzumab
- 7. Venetoclax + obinutuzumab
- 8. Other



What is your usual preferred initial regimen for a <u>60-year-old</u> patient with CLL with <u>unmutated IGHV</u> and no del(17p) or TP53 mutation who requires treatment?

Dr Davids	Venetoclax + obinutuzumab	Dr Mato	Venetoclax + obinutuzumab
Dr Flinn	Venetoclax + obinutuzumab	Dr Pagel	Acalabrutinib
Dr Hill	Venetoclax + obinutuzumab	Dr Rogers	Acalabrutinib or venetoclax + obinutuzumab
Dr Jain	Venetoclax + obinutuzumab	Dr Siddiqi	Venetoclax + obinutuzumab



What would be your most likely approach for a patient with newly diagnosed CLL to whom you administer up-front venetoclax/obinutuzumab who has <u>detectable</u> minimal residual disease (MRD) after 1 year of treatment?

- 1. Continue treatment
- 2. Discontinue treatment




What would be your most likely approach for a patient with newly diagnosed CLL to whom you administer up-front venetoclax/obinutuzumab who has <u>detectable</u> minimal residual disease (MRD) after 1 year of treatment?





What is your usual preferred initial regimen for a <u>60-year-old</u> patient with <u>del(17p)</u> CLL who requires treatment?






Which second-line systemic therapy would you recommend for a 60-year-old patient with CLL with no IGHV mutation and no del(17p) or TP53 mutation who responds to <u>ibrutinib</u> and then experiences disease progression 3 years later?

- 1. Acalabrutinib
- 2. Acalabrutinib + obinutuzumab
- 3. Venetoclax
- 4. Venetoclax + rituximab
- 5. Venetoclax + obinutuzumab
- 6. Idelalisib
- 7. Duvelisib
- 8. Other



Which second-line systemic therapy would you recommend for a 60-year-old patient with CLL with unmutated IGHV and no del(17p) or TP53 mutation who responds to <u>ibrutinib</u> and then experiences disease progression 3 years later?





Which second-line systemic therapy would you recommend for a 60-yearold patient with CLL with no IGHV mutation and no del(17p) or TP53 mutation who responds to <u>venetoclax/obinutuzumab</u> and then experiences disease progression 3 years later?

- 1. Ibrutinib
- 2. Ibrutinib + rituximab
- 3. Ibrutinib + obinutuzumab
- 4. Acalabrutinib
- 5. Acalabrutinib + obinutuzumab
- 6. Idelalisib
- 7. Duvelisib
- 8. Other



Which second-line systemic therapy would you recommend for a 60-year-old patient with CLL with unmutated IGHV and no del(17p) or TP53 mutation who responds to <u>venetoclax/obinutuzumab</u> and then experiences disease progression 3 years later?

Dr Davids	Venetoclax + obinutuzumab	Dr Mato	Venetoclax + rituximab
Dr Flinn	Acalabrutinib	Dr Pagel	Acalabrutinib
Dr Hill	Acalabrutinib	Dr Rogers	Ibrutinib
Dr Jain	Acalabrutinib	Dr Siddiqi	Acalabrutinib + obinutuzumab



A <u>60-year-old</u> patient with CLL, an absolute lymphocyte count of <u>80,000</u> and several involved lymph nodes that are <u>larger than 5 centimeters</u> is about to receive venetoclax. What preemptive measures, if any, would you take to address tumor lysis syndrome prior to the initiation of therapy?

Dr Davids	Admit to hospital	Dr Mato	Admit to hospital
Dr Flinn	Debulk with obinutuzumab	Dr Pagel	Admit to hospital
Dr Hill	Admit to hospital	Dr Rogers	Admit to hospital
Dr Jain	Admit to hospital	Dr Siddiqi	Admit to hospital



Meet The Professor with Dr Thompson

MODULE 1: Cases from Dr Allan

MODULE 2: Beyond the Guidelines

MODULE 3: Journal Club with Dr Thompson

- Occupy BTK: The key to controlling CLL
- Acalabrutinib for patients with relapsed/refractory CLL intolerant to ibrutinib
- Ibrutinib induces durable remissions in patients with treatment-naïve CLL with 17p deletion/TP53 mutations
- Achieving complete remission with ibrutinib: Clinical significance and predictive factors
- Prognostic value of measurable residual disease after venetoclax and decitabine for AML
- A multicenter Phase II study of venetoclax with dose-adjusted R-EPOCH (VR-EPOCH) for Richter's syndrome
- Clinical and molecular characteristics and treatment patterns of adolescents and young adults with CLL

MODULE 4: Key Recent Data Sets



LYMPHOID NEOPLASIA

Comment on Sun et al, page 93

Occupy BTK: the key to controlling CLL

Philip A. Thompson | The University of Texas MD Anderson Cancer Center

In this issue of *Blood*, Sun and colleagues present results from a randomized, phase 2 study of acalabrutinib at either 100 mg twice daily or 200 mg daily in patients with treatment-naive or relapsed/refractory chronic lymphocytic leukemia (CLL).¹ As part of the study, they undertook a rigorous analysis of Bruton tyrosine kinase (BTK) occupancy and the resulting biologic consequences in different tissue compartments. They established that twice-daily dosing achieved higher BTK occupancy and resultant downstream pathway inhibition in lymph nodes than once-daily dosing and established the rate of BTK resynthesis in CLL cells.

Blood 2020;136(1):4-6



Phase 2 Study of Acalabrutinib in Ibrutinib (IBR)-Intolerant Patients (pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Rogers KA et al. ASCO 2019;Abstract 7530.



Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-Up from a Phase 2 Study

Sivina M et al. ASH 2020;Abstract 2218.



Blood 2020;135(7):510-3

Letter to Blood

TO THE EDITOR:

Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

Paolo Strati,¹ Ellen J. Schlette,² Luisa M. Solis Soto,³ Daniela E. Duenas,³ Mariela Sivina,⁴ Ekaterina Kim,⁴ Michael J. Keating,⁴ William G. Wierda,⁴ Alessandra Ferrajoli,⁴ Hagop Kantarjian,⁴ Zeev Estrov,⁴ Nitin Jain,⁴ Philip A. Thompson,⁴ Ignacio I. Wistuba,³ and Jan A. Burger⁴



Prognostic Value of Measurable Residual Disease After Venetoclax and Decitabine in Acute Myeloid Leukemia

Maiti A et al. ASH 2020;Abstract 276.



ASCO 2020; Abstract 8004

MDAnderson Cancer Center





A Multicenter Phase 2 Study of Venetoclax plus Dose-Adjusted R-EPOCH (VR-EPOCH) for Richter's Syndrome

<u>Matthew S. Davids, MD, MMSc¹</u>, Kerry A. Rogers, MD², Svitlana Tyekucheva, PhD³, Samantha Pazienza, BS¹, Sarah K. Renner, RN⁴, Josie Montegaard, NP¹, Michael Rocchio, BA¹, Udochukwu Ihuoma, BA¹, Caron A. Jacobson, MD, MMSc¹, David C. Fisher, MD¹, Jennifer R. Brown, MD, PhD¹, and Philip A. Thompson, MB, BS (Hons)⁴

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
 ²Division of Hematology, The Ohio State University, Columbus, OH, USA
 ³Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA
 ⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

PRESENTED AT: 2020ASCO

#ASCO20

PRESENTED BY: Matthew S. Davids, MD, MMSc

1





American Society of Hematology Helping hematologists conquer blood diseases worldwide

MDAnderson Cancer Center

Making Cancer History*

Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia

Hua-Jay J Cherng, MD¹, Nadya Jammal, PharmD², Shilpa Paul, PharmD², Xuemei Wang, MS³, Koji Sasaki, MD¹, Philip A. Thompson, MBBS¹, Jan A. Burger, MD PhD¹, Alessandra Ferrajoli, MD¹, Zeev E. Estrov, MD¹, Susan M. O'Brien, MD⁴, Michael J. Keating, MBBS¹, William G. Wierda, MD

PhD¹, Nitin Jain, MD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX ²Department of Clinical Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX ³Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX ⁴Chao Family Comprehensive Cancer Center, University of Irvine, Orange County, CA

2020 ASH Annual Meeting

Abstract #1301



Meet The Professor with Dr Thompson

MODULE 1: Cases from Dr Allan

MODULE 2: Beyond the Guidelines

MODULE 3: Journal Club with Dr Thompson

- Occupy BTK: The key to controlling CLL
- Acalabrutinib for patients with relapsed/refractory CLL intolerant to ibrutinib
- Ibrutinib induces durable remissions in patients with treatment-naïve CLL with 17p deletion/TP53 mutations
- Achieving complete remission with ibrutinib: Clinical significance and predictive factors
- Prognostic value of measurable residual disease after venetoclax and decitabine for AML
- A multicenter Phase II study of venetoclax with dose-adjusted R-EPOCH (VR-EPOCH) for Richter's syndrome
- Clinical and molecular characteristics and treatment patterns of adolescents and young adults with CLL

MODULE 4: Key Recent Data Sets



Optimal Integration of BTK Inhibitors and Venetoclax into First-Line Treatment



The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE


Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

J.A. Woyach, A.S. Ruppert, N.A. Heerema, W. Zhao, A.M. Booth, W. Ding,
N.L. Bartlett, D.M. Brander, P.M. Barr, K.A. Rogers, S.A. Parikh, S. Coutre,
A. Hurria,* J.R. Brown, G. Lozanski, J.S. Blachly, H.G. Ozer, B. Major-Elechi,
B. Fruth, S. Nattam, R.A. Larson, H. Erba, M. Litzow, C. Owen, C. Kuzma,
J.S. Abramson, R.F. Little, S.E. Smith, R.M. Stone, S.J. Mandrekar, and J.C. Byrd

N Engl J Med 2018;379(26):2517-28.



Phase III Alliance A041202 Study Design




Primary endpoint: Progression-free survival (PFS) **Secondary endpoints:** OS, ORR, Impact of MRD on PFS and OS, Duration of response, Toxicity and Tolerability

Woyach JA et al. *N Engl J Med* 2018;379(26):2517-28. Woyach J et al. Alliance Fall Group Meeting, November 5, 2015.



Alliance A041202: Efficacy with Ibrutinib Alone or in Combination with Rituximab Compared to Bendamustine/Rituximab



Months

Woyach JA et al. N Engl J Med 2018;379(26):2517-28.

Alliance A041202: Grade 3 to 5 Adverse Events of Special Interest

Adverse event	Bendamustine + rituximab (N = 176)	Ibrutinib (N = 180)	lbrutinib + rituximab (N = 181)	<i>p</i> -value
Hematologic – Any Grade 3-4	61%	41%	39%	<0.001
Anemia	12%	12%	6%	0.09
Decreased neutrophil count	40%	15%	21%	<0.001
Decreased platelet count	15%	7%	5%	0.008
Nonhematologic – Any Grade 3-5	63%	74%	74%	0.04
Bleeding	0	2%	3%	0.46
Infections	15%	20%	21%	0.62
Febrile neutropenia	7%	2%	1%	<0.001
Atrial fibrillation	3%	9%	6%	0.05
Hypertension	15%	29%	34%	<0.001




Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-Up from the E1912 Trial

Shanafelt TD et al. ASH 2019;Abstract 33.



Phase III ECOG-ACRIN E1912 Study Design




Primary endpoint: PFS **Secondary endpoints:** OS, ORR, Toxicity and Tolerability

ECOG-ACRIN E1912 Physician Fact Sheet, version 01/15/16; www.clinicaltrials.gov (NCT02048813); Shanafelt TD et al. ASH 2018;Abstract LBA-4.



ECOG-ACRIN E1912 Extended Follow-Up: Up-Front IR Compared to FCR for Younger Patients with CLL



- Grade ≥3 treatment-related AEs were reported in 70% of patients receiving IR and 80% of patients receiving FCR (odds ratio = 0.56; *p* = 0.013).
- Among the 95 patients who discontinued ibrutinib, the most common cause was AE or complication.



Shanafelt TD et al. ASH 2019; Abstract 33.




Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel, Ian W Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutre, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A Woyach, Gilles Salles, William G Wierda, Raquel Izumi, Veerendra Munugalavadla, Priti Patel, Min Hui Wang, Sofia Wong, John C Byrd

Lancet 2020;395(10232):1278-91.



ELEVATE-TN Phase III Trial Schema




Primary endpoint: Progression-free survival



www.clinicaltrials.gov (NCT02475681). Accessed August 2020.







Sharman JP et al. *Lancet* 2020;395:1278-91.

ELEVATE-TN: Select Safety Parameters

	Acalabrutinib/obinutuzumab (n = 178)			rutinib 179)	Obinutuzumab/chlorambucil (n = 169)	
	Grade 1-2	Grade ≥3	Grade 1-2	Grade ≥3	Grade 1-2	Grade ≥3
Any AE	26%	70%	45%	50%	29%	70%
Serious AE	6%	33%	2%	30%	2%	20%
AE leading to drug discontinuation	11%		9%		14%	
Neutropenia	2%	30%	1%	10%	4%	41%
Grade ≥3 infections						
Infusion-related reactions	11%	2%	0	0	34%	5%



Acalabrutinib Met Primary Efficacy Endpoint in Head-to-Head Trial Against Ibrutinib for Chronic Lymphocytic Leukemia Press Release — January 25, 2021

"Positive high-level results from the ELEVATE-RR Phase III trial showed acalabrutinib met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk chronic lymphocytic leukemia (CLL) compared to ibrutinib.

The trial also met a key secondary endpoint for safety, showing patients treated with acalabrutinib had statistically significantly lower incidence of atrial fibrillation compared to patients treated with ibrutinib. Atrial fibrillation is an irregular heart rate that can increase the risk of stroke, heart failure and other heart-related complications. Further hierarchical testing revealed no difference for Grade 3 or higher infections or Richter's transformation. There was a descriptive trend for numerically favorable overall survival. Overall, the safety and tolerability of acalabrutinib were consistent with the profile seen in the broader acalabrutinib clinical development program.

ELEVATE-RR is the first Phase III trial to compare two Bruton's tyrosine kinase (BTK) inhibitors in patients with CLL, the most common type of leukemia in adults."




Ibrutinib (Ibr) plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results from the MRD Cohort of the Phase 2 CAPTIVATE Study Trial

Wierda WG et al. ASH 2020;Abstract 123.



CAPTIVATE Phase II Trial of First-Line Ibrutinib with Venetoclax for CLL: 1-Year DFS Results from the MRD Cohort



^aThe 3 DFS events in placebo arm were disease progression in 2 patients and MRD relapse in 1 patient.

30 month PFS Rate:

Confirmed uMRD:

- 95.3% placebo
- 100% ibrutinib

Without confirmed uMRD:


- 95.2% ibrutinib
- 96.7% ibr/ven

AEs were primarily Grade 1/2 and mostly occurred in early cycles of Ibr + Ven, with modest differences by randomized treatment arm.



Wierda WG et al. ASH 2020; Abstract 123.

Phase III EA9161 Schema








Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Othman Al-Sawaf, Can Zhang, Maneesh Tandon, Arijit Sinha, Anna-Maria Fink, Sandra Robrecht, Olga Samoylova, Anna M Liberati, Javier Pinilla-Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura M Fogliatto, Carsten U Niemann, Robert Weinkove, Sue Robinson, Thomas J Kipps, Eugen Tausch, William Schary, Matthias Ritgen, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Barbara Eichhorst, Stephan Stilgenbauer, Michael Hallek^{*}, Kirsten Fischer^{*}

Lancet Oncol 2020;21(9):1188-200.




CLL14: PFS by IGHV and TP53 Mutation Status





CLL14: Landmark Analysis from End of Therapy PFS by MRD Group






Al-Sawaf O et al. Lancet Oncol 2020;21(9):1188-200.

Clonal Dynamics After Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial

Al-Sawaf O et al. ASH 2020;Abstract 127.



CLL14 Phase III Study Schema



Primary endpoint: Progression-free survival

- Treatment duration in both groups: 12 cycles, 28 days each
- No crossover was allowed
- Daily oral venetoclax regimen:
 - Initiated on day 22 of cycle 1, starting with a 5-week dose ramp-up (1 week each of 20, 50, 100 and 200 mg, then 400 mg daily for 1 week)
 - Thereafter continuing at 400 mg daily until completion of cycle 12


www.clinicaltrials.gov (NCT02242942). Accessed August 2020. Fischer K et al. *N Engl J Med* 2019;380(23):2225-36.



CLL14: Updated 4-Year PFS

4-YEAR FOLLOW-UP: PROGRESSION-FREE SURVIVAL

Median observation time 52.4 months



Median PFS Ven-Obi: not reached Clb-Obi: 36.4 months

4-year PFS rate Ven-Obi: 74.0% Clb-Obi: 35.4%

HR 0.33, 95% CI [0.25-0.45] P<0.0001



Al-Sawaf O et al. ASH 2020; Abstract 127.

Management of Relapsed/Refractory CLL




Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Kater AP et al. ASH 2020;Abstract 125.



MURANO: 5-Year Follow-Up of Venetoclax/Rituximab (Ven/R) in R/R CLL



EOT, end of treatment; MRD, minimal residual disease; OS, overall survival; PB, peripheral blood; PD, progressive disease; pts, patients; Tx, therapy; uMRD, undetectable minimal residual disease; Ven, venetoclax.

- Median PFS for VenR: 53.6 mo
- 5 year OS rate: 82%
- Of 83 patients with uMRD at end of therapy, 38.5% remained uMRD
- 25 months was the average time from MRD conversion to requirement for therapy




Kater AP et al. ASH 2020; Abstract 125.

Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration VenR in the MURANO Study

Harrup R et al. ASH 2020;Abstract 3139.




MURANO: TTNT with VenR versus BR





Efficacy of Subsequent Novel Targeted Therapies in Patients Treated on the MURANO Trial: Conclusions





Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia Patients after a Previous Venetoclax-based Regimen

Meghan C. Thompson, MD¹, John N. Allan, MD², Kavita Sail, PhD³, Beenish S. Manzoor, PhD, MPH⁴, Jeffrey J. Pu, MD, PhD⁵, Paul M. Barr, MD⁶, Callie C. Coombs, MD⁷, Stephen J. Schuster, MD⁸, Alan Skarbnik, MD⁹, Joanna M Rhodes, MD¹⁰, Jacqueline C. Barrientos, MD¹⁰, Lindsey E Roeker, MD¹, Lori A. Leslie, MD¹¹, Manali Kamdar, MD¹², Michael Y. Choi, MD¹³, Martin Simkovic, MD, PhD¹⁴, Frederick Lansigan, MD¹⁵, Brittany Jane Hale, MD¹⁵, Andrew D Zelenetz, MD, PhD¹⁶, Alison J. Moskowitz, MD¹, Kurt S. Bantilan, MPH¹, Celina J. Komari, BS¹, Andre H. Goy, MD¹, Tatyana A. Feldman, MD¹¹, Richard R. Furman, MD² and Anthony R. Mato, MD¹



Study Design and Endpoints

- Multicenter, retrospective study
- 13 centers and the CLL Collaborative Study of Real-World Evidence (CORE) database
- Eligibility:
 - CLL patients treated with Ven-based regimen (any line of therapy, Ven1)
 - Then re-treated with second Ven-based regimen (Ven2) in a later line of therapy
- Data collected by investigators at individual sites
 - Demographics, prognostic disease characteristics, tumor lysis syndrome risk and incidence, clinical response and reasons for treatment discontinuation

- Primary endpoint:
 - Investigator-assessed ORR
 - CR: complete response, PR: partial response, SD: stable disease, PD: progression of disease, iwCLL 2018
- PFS estimated by Kaplan-Maier method
- All other analyses descriptive






Conclusions


- ORR: High ORR of 72.2% for Ven re-treatment
- Heavily pretreated population: Cohort studied had median 2 prior therapies, majority R/R (88%), BTKi exposed (60%)
- Safety: TLS rare event and majority were able to tolerate 400 mg daily
- Improved outcomes with time: Patients with CR to Ven re-treatment had a longer median follow-up than PR or SD patients
 - Potential for better responses with longer time on therapy?
- Next steps: Longer follow-up and prospective validation of Ven retreatment → potential role of Ven re-treatment in sequencing algorithms




Overview of BTK Inhibitors in CLL


Irreversible








Reversible










Courtesy of Matthew S Davids, MD, MMSc

LOXO-305 is a Highly Potent and Selective Non-Covalent BTK Inhibitor

Highly selective for BTK BT CMG

Kinome selectivity

Xenograft models *In vivo* activity similarly efficacious as ibrutinib in WT; superior in C481S



- Nanomolar potency against WT & C481-mutant BTK in cell and enzyme assays^{1,2}
- >300-fold selectivity for BTK vs 370 other kinases¹
- Due to reversible binding mode, BTK inhibition not impacted by intrinsic rate of BTK turnover¹
- Favorable pharmacologic properties allow sustained BTK inhibition throughout dosing interval¹

BID, twice-daily; BTK, Bruton tyrosine kinase. Illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com). ¹Brandhuber et al. Clin. Lymphoma Myeloma Leuk. 2018;18:S216. ²Mato et al. Blood. 2019:134 (Suppl 1):501.


Mato AR et al. ASH 2020; Abstract 542.

LOXO-305, a Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

Mato AR et al. ASH 2020;Abstract 542.



BRUIN: LOXO-305 for Previously Treated CLL/SLL (Median prior therapies: 4)



* 11 efficacy-evaluable pts are not included in the waterfall plot, including 1 pt who discontinued prior to first response assessment, and 10 pts (4 pts with PR/PR-L and 6 pts with SD) with incomplete tumor lesion measurement data at the time of data cut



BRUIN: Safety

Adverse Events, at All Doses and Patients (N=323), n (%)		Tr	Treatment-Emergent AEs, (≥10%)ª			Treatment-Related AEs	
		Any Grade	Grade 1	Grade 2	Grade 3	Any Grade	Grade 3/4
Fatigue		65 (20)	40 (12)	22 (7)	3 (1)	27 (8)	2 (<1)
Diarrhea		55 (17)	45 (14)	10 (3)	-	28 (9)	-
Contusion		42 (13)	37 (12)	5 (2)	-	29 (9)	-
AEs of special interest, ^{b,c}	Bruising	53 (16)	48 (15)	5 (2)	-	37 (12)	-
	Rash	35 (11)	30 (9)	5 (2)	-	18 (6)	-
	Arthralgia	16 (5)	13 (4)	3 (1)	-	5 (2)	-
	Hemorrhage	15 (5)	10 (3)	4 (1)	1 (<1) ^d	5 (2)	-
	Hypertension	15 (5)	2 (<1)	9 (3)	4 (1)	4 (1)	-
	AFib/Flutter	2 (<1)	-	2 (<1) ^e	-	-	-

- No DLTs reported and MTD not reached
- 5 (1.5%) discontinued due to treatment-related AEs
- 200 mg QD selected as recommended phase 2 dose




Updated Follow-Up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients

Siddiqi T et al. ASH 2020;Abstract 546.



TRANSCEND CLL 04: Liso-cel Monotherapy Cohort



- ORR/CR = 82%/68%
- Median PFS 13 mo and DOR 50% at 12 mo
- Gr 3 CRS= 9% and NE 22% (No Grade 4/5)
- 4 of 6 progressions due to RT



Siddiqi T et al. ASH 2020; Abstract 546.

Meet The Professor Immunotherapy and Novel Agents in Gynecologic Cancers

> Monday, April 5, 2021 5:00 PM – 6:00 PM ET

Faculty Bradley J Monk, MD

> Moderator Neil Love, MD



Thank you for joining us!

CME and MOC credit information will be emailed to each participant within 5 business days.

